Montelukast Prescribing at MAPLE ACCESS PARTNERSHIP LLP
Cromoglycate, leukotriene and phosphodesterase type-4 inhib | Respiratory System
Items (12m)
1,719
Total Quantity
28.5K
NHS Cost
£1.4K
vs National Avg
+151%
MAPLE ACCESS PARTNERSHIP LLP prescribed 1,719 items of Montelukast over the last 12 months at a cost of £1,447 to the NHS. This is 151% above the national average prescribing rate. Montelukast is classified under Cromoglycate, leukotriene and phosphodesterase type-4 inhib in the BNF.
Monthly Prescribing Trend
Jun 2026
135
Jun 2026
122
Jun 2026
137
Jun 2026
132
Jun 2026
132
Jun 2026
139
Jun 2026
126
Jun 2026
158
Jun 2026
142
Jun 2026
132
Jun 2026
207
Jun 2026
157
Prescribing Details
| Total Items | 1,719 |
|---|---|
| Total Quantity | 28,482 |
| Total NHS Cost | £1,447 |
| Presentations | 4 different forms |
| vs National Average | +151% |
Montelukast Prescribing Comparison
| This practice | 1,719 items |
|---|---|
| National average per practice | 685 items |
| Difference | +151% vs national average |
Explore More
Data sourced from NHSBSA English Prescribing Dataset, CQC, and GP Patient Survey. Prescribing data does not indicate quality of care. Higher prescribing rates may reflect patient demographics. Always consult your GP for medical advice.